WaferiX

Novel sublingual wafer platform technology

Superior drug delivery

  • Increased bioavailability
  • Rapid onset of therapeutic action
  • Predictable effect
  • Convenient
  • Fixed unit dose

Patented platform technology

  • Delivers small molecules across a range of indications
  • Globally patented

Proprietary manufacturing process

  • Freeze-dried solid dosage form
  • In-house expertise
  • TGA compliant
  • GMP facility

Repurposing drugs
with WaferiX

IMPROVING THE DELIVERY OF ACTIVE COMPOUNDS
  • are poorly absorbed when swallowed
  • can only be administered intravenously
  • require rapid onset of action
  • benefit from product life-cycle extension

Repurposed drugs have superior delivery and absorption, improved patient compliance and renewed market exclusivity.

TREATING NEW INDICATIONS USING APPROVED ACTIVES

Approved active compounds have established safety and toxicity profiles. We reposition these actives for new indications with unmet medical needs. Leveraging on expedited pathways like FDA 505(b)(2), development risks and costs are lowered with faster speed to market.

We develop innovative therapies that improve the quality of life for patients with pain, chronic diseases and debilitating conditions.

Our Product Portfolio

Pharmaceutical Products

We have a robust pipeline of CNS products that are being developed and clinically evaluated. Our portfolio includes Wafermine (sublingual ketamine) for pain and depression, BnoX (sublingual buprenorphine) for pain, and Wafesil (sublingual sildenafil) for erectile dysfunction.

Medicinal Cannabis Products

Our revolutionary sublingual cannabis wafers for medicinal and supplement use have been awarded “CBD Product of the Year 2020” by the Australian Cannabis Awards.

Nutraceutical Products

Entity, our next-generation nutraceuticals, combine unique, clinically backed formulations and superior delivery for products targeting specific conditions.

Wafermine

Our lead product under development is a sublingual racemic ketamine wafer which is being evaluated for the treatment of acute moderate to severe pain.

Phase 3-ready, positive results in Phase 2b

  • strong analgesic effect
  • safe and tolerable
  • non-opioid with opioid sparing effects
LEARN MORE

Strengths at every stage of the development chain

Fully integrated from R&D, manufacturing, regulatory affairs to sales.

Better Operating Efficiencies

End-to-end service, faster speed to market

Quality Control

Fully licensed, TGA-compliant cGMP facility.

Intellectual Property Protection

Proprietary freeze-drying process supported by highly trained professionals and specialised equipment.

Latest Announcements

VIEW ALL

iX Biopharma Ltd is pleased to announce positive results from a single-dose pharmacokinetic study demonstrating that iXB 401, a novel semaglutide sublingual wafer, achieved significantly greater bioavailability—approximately 20 times higher—than the oral semaglutide tablet Rybelsus® in a preclinical study conducted in 12 Sprague-Dawley rats.

More information on the press release can be found here.

Please see "A Single-Dose Pharmacokinetic Study of a Novel Sublingual Semaglutide Wafer in Rats" for the technical report.

iX Biopharma Ltd is pleased to announce that Dr. Brian Kennedy, PhD, has joined its Scientific Advisory Board (SAB) as a scientific advisor.

Dr. Kennedy brings immense expertise in the field of aging and longevity, supporting iX Biopharma’s aim to develop and market NAD+ and other healthspan supplements through its supplements arm, Entity Health.

More information on the press release can be found here.

iX Biopharma Ltd has announced that an Extraordinary General Meeting of the company will be held at 2 Science Park Drive, Ascent Main Lobby, The Metro, Singapore 118222 on Thursday, 17 October 2024 at 11.00 a.m. (or as soon as practicable immediately following the conclusion or adjournment of the 2024 AGM to be held at 10.00 am). The relevant documents can be found below.

Notice of EGM and Proxy Form

Circular for Extension of Schemes

iX Biopharma Ltd has released the Notice of AGM and AGM Proxy Form for the upcoming Annual General Meeting of the company to be held on Thursday, 17 October 2024 at 10.00am. The Annual General Meeting will be held at 2 Science Park Drive, Ascent Main Lobby, The Metro, Singapore 118222. The forms can be found in the link below.

Notice of AGM & Proxy Form

iX Biopharma Ltd has published both its Annual Report & Sustainability Report for FY2024. The respective reports can be found below.

Annual Report FY2024

Sustainability Report FY2024


iX Biopharma Ltd has released the auditor’s comment of accounts for the company.

Auditors Comments of Accounts